Guardant Health is leveraging star power to market its innovative Shield blood test for colorectal cancer screening, recruiting actor James Van Der Beek as a brand ambassador. Van Der Beek, who publicly revealed his own stage 3 colon cancer diagnosis in November 2024, brings powerful personal testimony to the campaign. The partnership targets a substantial untapped market of over 50 million Americans aged 45+ who currently avoid traditional, invasive screening methods. The National Comprehensive Cancer Network has already included Shield, the first FDA-approved blood test for primary colorectal cancer screening, in its updated guidelines—a significant milestone for market acceptance.
Billion-Dollar Market Potential
The stark statistics underscore Shield’s market opportunity: 75% of colorectal cancer deaths occur in unscreened patients, while early detection boosts five-year survival rates from just 13% in late stages to over 90%. With more than 50,000 annual colorectal cancer deaths in the US alone, Shield’s blood-based alternative to conventional screening methods positions Guardant Health to capture a significant share of this rapidly growing market. Even a modest penetration into the currently unscreened population could substantially drive the company’s revenue growth.
Ad
Guardant Health Stock: Buy or Sell?! New Guardant Health Analysis from February 7 delivers the answer:
The latest Guardant Health figures speak for themselves: Urgent action needed for Guardant Health investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.
Guardant Health: Buy or sell? Read more here...
